CorrêaCR, GarciaJL. DNA Damage in Chronic Heart Failure: Consequences Beyond those in the Heart. Arq. Bras. Cardiol. 2020;114(2):243-4.
Corrêa,Camila Renata; Garcia,Jéssica Leite. DNA Damage in Chronic Heart Failure: Consequences Beyond those in the Heart. Arq. Bras. Cardiol., v. 114, n. 2, p. 243-244, Feb. 2020.
Corrêa,C.R., & Garcia,J.L. (2020). DNA Damage in Chronic Heart Failure: Consequences Beyond those in the Heart. Arq. Bras. Cardiol.,114(2), 243-244.
Corrêa,Camila Renata and Garcia,Jéssica Leite. DNA Damage in Chronic Heart Failure: Consequences Beyond those in the Heart. Arq. Bras. Cardiol. [online]. 2020, vol. 114, n. 2, [cited 2025-09-06], pp.243-244. Available from: <https://abccardiol.org/en/short-editorial/dna-damage-in-chronic-heart-failure-consequences-beyond-those-in-the-heart/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.
